Suprefort vs Vilon
Suprefort and Vilon research, with limited Vilon human reports and unresolved clinical questions.
Last updated: September 9, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Suprefort
Dossier overview
Vilon
Dossier overview
Overview
Suprefort and Vilon are both studied in the peptide research space.
Suprefort: A cytamin-class peptide supplement derived from pancreatic tissue, part of the Russian bioregulator framework.
Vilon: A synthetic dipeptide (Lys-Glu) developed by Russian scientist Vladimir Khavinson as part of the peptide bioregulation framework.
Evidence Comparison
Vilon evidence scope (September 9, 2026)
Vilon’s selected bibliography contains 25 publications: five human-containing reports, 17 preclinical experimental reports and three review or synthesis documents. These are publication counts, not five independent clinical trials or a complete literature census. Human cell cultures belong to the preclinical group; some reports examine several peptides. Possible cohort reuse, including the two diabetes reports, remains unresolved. Counts and inherited catalogue grades do not establish clinical equivalence or superiority between these compounds.
Three indexed reports describe adjunctive Vilon in diabetes or colorectal-cancer care. One diabetes paper is indexed as a randomized controlled trial, but the retained abstracts do not provide sufficient allocation, sample-size, safety or outcome detail to establish reliable clinical benefit. Diabetes report, second diabetes report, colorectal-cancer report.
Two 2022 publisher documents report oral supplement use: a 520-person convalescence account and a 98-person gastritis study alongside standard eradication therapy. Reporting and product-characterization limitations remain. The gastritis study found no statistically significant gastric pH changes; its symptom-response counts conflict with the reported means. The convalescence immune-marker table reports within-group significance, which alone does not establish a treatment effect versus placebo. These reports do not establish oral pharmacokinetics or routine immune-support efficacy. Convalescence report, gastritis report.
The May 2025 dentistry publication is a review of older clinical material, not a new trial. Its Vilon, combined-treatment and mixed-peptide accounts cannot be counted as independently confirmed native-Vilon cohorts. Dentistry review.
Safety is inadequately characterized in people. Animal findings include increased mammary-tumour incidence in a HER2/neu mouse model and reduced survival with synchronous Vilon and cyclophosphane in a different mouse cancer experiment. These findings do not quantify human risk, but they preclude a blanket safety or combination-compatibility claim. HER2/neu mouse report, mouse combination report.
| Aspect | Suprefort | Vilon |
|---|---|---|
| Evidence Level | Very Low | Clinical certainty not formally graded |
| Human Studies | 0 | 5 human-containing reports; independence unresolved |
| Preclinical Studies | 5 | 17 experimental reports; mixed models |
| Total Sources | 6 | 25 selected publications |
Key Differences
| Aspect | Suprefort | Vilon |
|---|---|---|
| Category | Other | Immune |
| Evidence Strength | Very Low | Clinical certainty not formally graded |
| Total Sources | 6 | 25 selected publications |
| Human Studies | 0 | 5 human-containing reports; independence unresolved |
Summary
- Suprefort: Very Low evidence with 6 total sources (0 human)
- Vilon: 25 selected publications, including five human-containing reports; clinical benefit and safety remain uncertain.
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.